A Clinical Trial of the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss
A legfontosabb adatok
- Ki végzi
- Yilai Shu
- Hol
- Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2025. jún. 7.
- Várható befejezés
- 2027. ápr.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
- A vizsgált kezelések
- TJ0113 capsules
- Placebo capsules
- A regiszteradat frissítve
- 2025. június 10.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for older adults with hearing loss caused by aging. It tests TJ0113 capsules against placebo (a dummy capsule).
- Életkor
- The criteria say 65 to 80 years. The record's age fields say 65 to 75 years.
- Nem
- All sexes can join. Women must be past menopause (over 24 months).
- A betegség stádiuma
- Hearing loss of the inner ear or hearing nerve, about the same in both ears, for more than 3 months. The difference between ears must be under 15 dB HL. Hearing loss must be moderate to severe (over 35dB and under 80dB).
- Korábbi kezelés
- No hearing aids used before. Or hearing aids used regularly for more than 3 years and stopped 3 months before joining.
A részvétel fő kizáró okai
- Implants in the study ear, recent ear infection, ear surgery or injury, Meniere's disease or other ear problems
- Hearing loss from causes other than aging, such as inherited, drug-related or noise-related, or loss in one ear only
- Work sensitive to sound, or frequent loud noise or loud headphone use
- Serious or unstable illness, including serious heart disease or uncontrolled high blood pressure
- Past hepatitis B, or positive test for hepatitis B, hepatitis C, HIV or syphilis
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- The subjects voluntarily participate in the clinical trial, sign the informed consent form, understand and follow the protocol, and fully understand the test content, process and possible adverse reactions
- Age between 65 and 80 years (including the critical value)
- A diagnosis of symmetrical sensorineural deafness (SNHL) with a history of> 3 months (binaural threshold difference in mean PTA frequency <15 dB HL), the PTA level should be between moderate (> 35dB) and severe (<80dB) hearing loss
- Hearing aids have not been used, or otherwise, it should be used regularly for more than 3 years and stopped for 3 months before enrollment
- Subjects and their partners had no birth plan, sperm or egg donation plans from the screening period until within 6 months after the end of the trial and would voluntarily take effective contraception (e. g. abstinence, condoms, etc.). Male subjects should agree to avoid sperm donation within 6 months from the start of administration until cessation of study treatment. Female subjects should be menopausal (over 24 months)
Ki nem vehet részt
- The presence of implants in the study ear (such as cochlear implant, artificial hearing bone, etc.)
- Suffering from acute otitis media or other ear infection within the previous 3 months or previous chronic suppurative otitis media or tympanic membrane perforation, or with conductive deafness, previous history of ear trauma or surgery, combined middle ear or inner ear malformation, otosclerosis, Meniere's disease, sudden deafness and no recovery of hearing, all of which will impact results explained
- Patients with sensorineural deafness caused by non-aging factors (e. g., hereditary deafness, congenital deafness, drug-induced deafness, noise deafness, neurosyphilis, severe retrocochlear lesions or organic lesions), and unilateral deafness
- Use headphones at high volume or frequent exposure to noise in previous work or life
- History of alcohol or drug dependence / drug abuse in the last 1 year
- Positive pregnancy test at screening or at the baseline visit, pregnant, lactating, or planned to become pregnant during the trial; 7.Failure to swallow oral medication, or, according to the investigator, any conditions that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or that may pose a hazard to the subjects participating in this trial; 9.People who currently taking drugs that can improve symptoms such as dementia and depression 10.Subjects with a severe or unstable systemic disease, such as serious congenital disease, blood disease, endocrine disease, nerve or nervous system disease, end-stage disease, head and neck tumor radiotherapy and chemotherapy history, major surgical treatment, psychological disorders (severe insomnia, severe depression, severe anxiety, etc. diagnosed within the previous 90 days ) or history and clinical significance of abnormal baseline laboratory values, such as hepatic insufficiency (alanine transaminase (ALT) and / or alanine transaminase (AST) is 2 times above the upper limit of the reference range, or renal insufficiency (creatinine clearance Ccr <30 mL/min), or history of malignant tumors and the detection results of tumor markers during the screening period have clinical significance, or unsuitable participants, as judged by the investigator; 11.Subjects suffering from any one of the following heart diseases: a. having uncontrolled or serious cardiovascular and cerebrovascular disease, including the development of grade II ( New York Heart Association, NYHA) or above congestive heart failure, unstable angina, acute myocardial infarction within 6 months before the first drug administration, or cardiac arrhythmias requiring treatment at screening; With b. hypertension (systolic pressure≥ 160mmHg and / or diastolic v≥ 100mmHg), and after the combination of two or more antihypertensive drugs can not be reduced to the normal range; or c.with a history of clinically significant ECG abnormalities, the QRS time was> 120ms, Long QT syndrome: QTc interval> 450ms in male or QTc interval> 470ms in female; 12.Participated in a clinical study involving the administration, device, or surgery of the study drug (new chemical entity) within 90 days or 5 half-lives (whichever is longer) 13.Patients with a previous history of hepatitis B, or any of the following indicators are positive at screening: hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody; 14.The subject is not fit to participate in the study if the investigator considers. Or the subject could not participate in the trial for his own reasons, or the behavior subject may interfere with treatment, study or interpretation of results (e. g., previous treatment with high-dose aminoglycosides)
- Occupation that is sensitive to sound: musician, conductor, music teacher, etc
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 65 és 75 év között vagy?
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of this study is to explore the safety and efficacy of TJ0113 capsules in patients with age-related hearing loss.
A vizsgálat 2 csoportja
- TJ0113 groupA vizsgált kezelés
Participants will be treated with TJ0113 capsule 200 mg daily for up to 24 weeks
Kezelés: TJ0113 capsules
- Placebo groupPlacebo, összehasonlításként
Participants will be treated with a placebo 200 mg daily for up to 24 weeks
Kezelés: Placebo capsules
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Randomized, Double-Blind, Placebo-Parallel-Controlled Clinical Trial to Explore the Safety and Efficacy of TJ0113 Capsules in the Treatment of Patients With Age-related Hearing Loss
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT07012746: ki vehet részt
- A regiszteradat frissítve
- 2025. június 10.